Damora Therapeutics (DMRA) Long-Term Investments (2021 - 2023)
Damora Therapeutics posted quarterly Long-Term Investments of $4.0 million for Q1 2023, down 51.42% year-on-year from $8.2 million in Q1 2022, and down 32.03% on a QoQ basis from $5.8 million in Q4 2022.
Damora Therapeutics (DMRA) has 3 years of Long-Term Investments data on file, last reported at $4.0 million in Q1 2023.
- For the quarter ending Q1 2023, Long-Term Investments fell 51.42% year-over-year to $4.0 million; the trailing twelve-month figure through Mar 2023 stood at $4.0 million (down 51.42% YoY), and the FY2022 full-year result was $5.8 million, down 35.54% from the prior year.
- Long-Term Investments for Q1 2023 stood at $4.0 million, down from $5.8 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $38.6 million in Q1 2021 and bottomed at $4.0 million in Q1 2023.
- The 3-year median for Long-Term Investments is $8.2 million (2022), against an average of $15.6 million.
- Peak annual rise in Long-Term Investments reached 35.54% in 2022, while the deepest fall reached 80.79% in 2022.
- A 3-year view of Long-Term Investments shows it stood at $9.0 million in 2021, then plunged by 35.54% to $5.8 million in 2022, then plunged by 32.03% to $4.0 million in 2023.
- The last three Long-Term Investments figures came in at $4.0 million (Q1 2023), $5.8 million (Q4 2022), and $6.8 million (Q3 2022), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 505,194.89 |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 5.75 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 9.79 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 22.17 Mn |
| 10 | Damora Therapeutics | 853.36 Mn | 650.97 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 3.96 Mn |
| Dec 31, 2022 | 5.83 Mn |
| Sep 30, 2022 | 6.83 Mn |
| Jun 30, 2022 | 6.89 Mn |
| Mar 31, 2022 | 8.16 Mn |
| Dec 31, 2021 | 9.05 Mn |
| Sep 30, 2021 | 25.49 Mn |
| Jun 30, 2021 | 35.86 Mn |
| Mar 31, 2021 | 38.58 Mn |